Literature DB >> 35999290

ARROW: pralsetinib hits target across cancers.

David Killock1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35999290     DOI： 10.1038/s41571-022-00683-5

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   65.011


× No keyword cloud information.
  2 in total

1.  Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.

Authors:  F Griesinger; G Curigliano; M Thomas; V Subbiah; C S Baik; D S W Tan; D H Lee; D Misch; E Garralda; D-W Kim; A J van der Wekken; J F Gainor; L Paz-Ares; S V Liu; G P Kalemkerian; Y Houvras; D W Bowles; A S Mansfield; J J Lin; V Smoljanovic; A Rahman; S Kong; A Zalutskaya; M Louie-Gao; A L Boral; J Mazieres
Journal:  Ann Oncol       Date:  2022-08-13       Impact factor: 51.769

2.  Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.

Authors:  Vivek Subbiah; Philippe A Cassier; Salvatore Siena; Elena Garralda; Luis Paz-Ares; Pilar Garrido; Ernest Nadal; Jacqueline Vuky; Gilberto Lopes; Gregory P Kalemkerian; Daniel W Bowles; Mahesh Seetharam; Jianhua Chang; Hui Zhang; Jennifer Green; Alena Zalutskaya; Martin Schuler; Yun Fan; Giuseppe Curigliano
Journal:  Nat Med       Date:  2022-08-12       Impact factor: 87.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.